Result: In our previous studies, drug selections with the subtype C 4742 strain, the G118R resistance pathway arose with DTG and the Merck investigational MK2048.
Result: The development of the G118R resistance was ascribed to a signature natural polymorphism at codon 118 in isolate 4742.
Discussion: In previous studies, subtype C variant, 4742, developed the G118R mutation in cell culture selections with DTG and Merck investigation INSTI, MK2048.
Discussion: The development of G118R was associated with a rare GGA natural polymorphism at codon 118, facilitating a G to A transition leading to G118R (AGA).
Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
Introduction: These observations were corroborated by in vitro analysis of resistance profiles which also uncovered two atypical INSTI resistance mutations (G118R and F121Y) that confer pan-INSTI resistance.
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
Method: 26, September 2016), HIV-GRADE (http://www.hiv-grade.de, version January 16, 2017), and Rega (https://rega.kuleuven.be/cev/avd/software/rega-algorithm, v9.0.1, October 29, 2013) were considered: A49G, H51Y, V54I, L68IV, L74I, E92V, Q95K, H114Y, G118R, S119R, T124A, A128T, E138T, G140C, Y143AGS, P145S, Q146IKLPR, Q148EG, PMID: 29070877
2017
Scientific reports
Abstract: We also compared dolutegravir-binding to PFV F190Y, G187R and S217K mutants, corresponding to HIV-1 F121Y, G118R and G140S/Q148K mutations that confer low-to-high resistance levels against raltegravir/dolutegravir.
Introduction: Our findings define a new approach to study the binding properties of DTG to IN and reach deeper insight into the mechanisms of drug resistance mutations such as G187R, F190Y and S217K (equivalent to G118R, F121Y and G140S/Q148K mutations, respectively, in INHIV).|mg
Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
PMID: 28923862
2017
Antimicrobial agents and chemotherapy
Abstract: In single cycle SIV infections, none of the E92Q, T97A, Y143R, or N155H substitutions had a significant effect on susceptibility to BIC (<=4-fold increase in EC50), whereas G118R and R263K conferred ~14-fold and ~6-fold increases in EC50, respectively.
Analysis of transmitted HIV drug resistance from 2005 to 2015 in Victoria, Australia: a comparison of the old and the new.
Abstract: One patient was detected with a major INI resistance mutation, namely G118R.
HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters.
PMID: 28472323
2017
The Journal of antimicrobial chemotherapy
Introduction: Dolutegravir is far less prone to the development of resistance in first-line therapy with isolated reported cases of the emergence of R263K, N155H or G118R.
Discussion: Our previous studies also showed the development of G118R (GGA AGA) in two patients failing dolutegravir monotherapy.
Discussion: Resistance to dolutegravir has, however, been limited to the G118R case and a novel resistance pathway from a raltegravir-experienced patient harbouring the N155H mutation.
Discussion: These patients harboured a rare GGA natural polymorphism (1.5% prevalence) compared with the majority of clinical viral isolates harbouring GGC (79%) or GGT (18%) glycine motifs where G118R acquisition would require two point mutations (GGG
Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
PMID: 28369593
2017
The Journal of antimicrobial chemotherapy
Abstract: Although dolutegravir may allow successful rescue in most HIV-2 raltegravir failures, we report and characterize three cases of dolutegravir resistance in HIV-2 patients, emerging variants Q148K and Q148R and a novel change G118R.
Abstract: In two of them N155H was replaced by Q148K/R and in another by G118R.
Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.
Discussion: Besides the Q148 mutation combined with one or more of G140A/C/S, L74I and E138A/K/T was identified to reduce viral susceptibility to dolutegravir, two amino acid mutations, G118R and R263K, have been reported to confer low-level resistance to dolutegravir.
Discussion: In our study, we did not identify any G118R substitution in our specimens, yet the prevalence of R263K was 0.31% and 1.64% in INSTI-naive and raltegravir-experienced patients, respectively.
HIV mutation literature information.
PMID: 
2018
Retrovirology
Browser Board
Co-occurred Entities
Filtrator
ViMRT